Journal · Pharmacology · Updated 21 November 2026
Inflammopharmacology
Read Inflammopharmacology articles on DeepDyve. No university library needed.
Inflammopharmacology has published since 1991 and covers inflammation and the drugs and natural compounds that act on it, in conditions from arthritis and wound healing to Parkinson’s and Alzheimer’s disease. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Inflammopharmacology at a glance
- Full title
- Inflammopharmacology
- Abbreviation (NLM)
- Inflammopharmacology
- Publisher
- Springer Nature
- Print ISSN
- 0925-4692
- Online ISSN (eISSN)
- 1568-5608
- First published
- 1991
- Subjects
- Drug Therapy, Pharmacology
- Access model
- Hybrid (22% free to read in 2026)
Ways to access Inflammopharmacology
22% of the articles Inflammopharmacology published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 22% of Inflammopharmacology articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Inflammopharmacology. Check its journal list and whether it offers remote access.
- DeepDyve. Read Inflammopharmacology articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Inflammopharmacology’s 2025 Journal Impact Factor is 6.3, and its 5-year Impact Factor is 6.0.
6.3
Journal Impact Factor (2025)
6.0
5-year Impact Factor (2025)
6 days
Median time to first decision
1.2M
Downloads (2025)
Source: journal metrics on the Inflammopharmacology homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Inflammopharmacology research worth reading
Published January to April 2026. Summaries describe what the authors report.
-
Polycystic ovary syndrome (PCOS): current insights, emerging therapeutics, and future treatment strategies
Panchpuri and colleagues review polycystic ovary syndrome as a multisystem syndrome, covering diagnostic criteria, lifestyle modification and insulin sensitizers as standard management in obese women, and emerging insulin-sensitizing options such as GLP-1 receptor agonists, SGLT2 inhibitors and DPP-4 inhibitors.
Panchpuri et al. · Inflammopharmacology, published online January 30, 2026 · DOI 10.1007/s10787-026-02117-5
-
Anti-inflammatory activity of Silver Nanoparticles (AgNPs): An Updated Systematic review from in vivo, and in vitro studies
Nair and colleagues review in vivo and in vitro studies from 2015 to 2025 on the anti-inflammatory potential of silver nanoparticles, including evidence that they inhibit NF-κB and MAPK signaling and suppress pro-inflammatory cytokines, along with toxicological challenges and safety considerations.
Nair et al. · Inflammopharmacology, published online February 26, 2026 · DOI 10.1007/s10787-026-02167-9
-
NLRP3 inflammasome and Alzheimer’s disease: bridging inflammation and neurodegeneration
Wasim and colleagues review the role of the NLRP3 inflammasome in neuroinflammation in Alzheimer’s disease, noting animal studies in which its inhibition or genetic deletion reduced amyloid burden and cognitive decline, and challenges of drug selectivity and blood–brain barrier penetration.
Wasim et al. · Inflammopharmacology, published online January 5, 2026 · DOI 10.1007/s10787-025-02092-3
-
Molecular insights into glial neuroimmune cross reactivity with CNS antigens and its role in neuroinflammation
Yadav and colleagues review glial and neuroimmune interactions in neuroinflammation, including cytokine signaling, glial activation and blood–brain barrier modulation across conditions such as multiple sclerosis, Alzheimer’s and Parkinson’s disease, and discuss in vitro models such as organ-on-a-chip platforms and brain organoids.
Yadav et al. · Inflammopharmacology, published online February 19, 2026 · DOI 10.1007/s10787-026-02113-9
-
HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches
Ibrahim and colleagues review HMGB1 signaling in neuroinflammation through receptors such as TLR4 and RAGE, its implication in disorders including ischemic stroke, Alzheimer’s disease and epilepsy, and therapeutic strategies that have shown benefit in experimental and preclinical models, while clinical validation remains limited.
Ibrahim et al. · Inflammopharmacology, published online April 11, 2026 · DOI 10.1007/s10787-026-02211-8
Related journals
Questions about Inflammopharmacology
How can I read Inflammopharmacology articles without a subscription?
22% of Inflammopharmacology articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Inflammopharmacology articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Inflammopharmacology?
Inflammopharmacology isn’t abbreviated: its NLM (PubMed) abbreviation is simply Inflammopharmacology.
What is the ISSN of Inflammopharmacology?
The print ISSN is 0925-4692 and the online ISSN is 1568-5608.
What is the impact factor of Inflammopharmacology?
Inflammopharmacology’s Journal Impact Factor is 6.3 (2025), and its 5-year Impact Factor is 6.0, according to Springer Nature’s published metrics.
Is Inflammopharmacology open access?
Inflammopharmacology is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 78 of 349 Inflammopharmacology articles (22%) carry a Creative Commons license, per Crossref.
Inflammopharmacology articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.
Start reading Inflammopharmacology today
One month free, then less than $2 a day. Inflammopharmacology, plus millions of articles from thousands of journals.





